Shamburg News · 8-K filed Nov 10, 2026, 4:18 PM EST

BridgeBio Oncology Therapeutics Reports Third Quarter 2026 Financial Results and Net Loss

BBOT · BridgeBio Oncology Therapeutics, Inc.

  • Earnings
  • Materiality: high

BridgeBio Oncology Therapeutics, Inc. reported financial results for the quarter ended September 30, 2026, with a net loss of $34.2 million, or $0.43 per share, compared with a net loss of $44.8 million in the third quarter of 2025. R&D expenses were $29.6 million and G&A expenses were $7.9 million for the quarter. As of September 30, 2026, cash, cash equivalents and marketable securities totaled $315.3 million, which the company expects to fund operations into 2029.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001193125-26-455506.

Written from the filing by Shamburg Markets. Figures are as reported by the company.